A5091418102- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Intensive Care Unit Cognitive Disorders
- Long-Term Effects of COVID-19
- Respiratory Support and Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Smoking Behavior and Cessation
- Multiple Sclerosis Research Studies
- BRCA gene mutations in cancer
- Optimism, Hope, and Well-being
- Ethics in Clinical Research
- Heart Failure Treatment and Management
- Respiratory and Cough-Related Research
- Prenatal Screening and Diagnostics
- Clinical practice guidelines implementation
- Restraint-Related Deaths
- Venous Thromboembolism Diagnosis and Management
- Autoimmune and Inflammatory Disorders Research
- Nosocomial Infections in ICU
- Pharmaceutical Economics and Policy
- COVID-19 and healthcare impacts
- Rheumatoid Arthritis Research and Therapies
- Plant Toxicity and Pharmacological Properties
- Silymarin and Mushroom Poisoning
- Cardiac Arrest and Resuscitation
EVERSANA (Canada)
2021-2023
Meharry Medical College
2021
Sherman Hospital
2021
Oxford University Hospitals NHS Trust
2020
E Ink (South Korea)
2009
Piedmont Atlanta Hospital
2006
Since August 2019, CDC, the Food and Drug Administration (FDA), state local health departments, public clinical stakeholders have been investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). This report updates patient demographic characteristics, self-reported substance use, hospitalization dates for EVALI patients reported to CDC by states, as well distribution emergency department (ED) visits related products analyzed through National...
This report provides a nationwide comparison of clinical characteristics e-cigarette, or vaping, product use–associated lung injury patients who were rehospitalized died after hospital discharge
CDC, the Food and Drug Administration (FDA), state local health departments, public clinical stakeholders continue to investigate a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). EVALI patients in Illinois, Utah, Wisconsin acquired tetrahydrocannabinol (THC)-containing products primarily from informal sources (2,3). This report updates demographic characteristics self-reported THC- nicotine-containing derived patient data reported CDC by...
Drug-induced liver disease accounts for about 50% of acute or subacute failure in the United States. Network Organ Sharing (UNOS) data suggest 8%-20% transplantation this country per year is fulminant due to drugs. Even though most common medication implicated injury acetaminophen (75%), there are numerous other drugs that responsible and chronic injury. A variety antifungal medications known cause a wide range from mild hepatocellular-cholestatic pattern acute/subacute failure. Terbinafine...
Ofatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada. The aim this study was to evaluate the cost effectiveness ofatumumab from Canadian healthcare system perspective. A Markov cohort model run over 65 years using annual cycles, 1.5% discount rate, and 100% discontinuation at 10 years. British Columbia database informed natural history transition probabilities. Treatment efficacy DMTs were...
Estimate the clinical and economic benefits of lenzilumab plus standard care (SOC) compared with SOC alone in treatment patients hospitalized COVID-19 pneumonia from United States (US) hospital perspective.A per-patient cost calculator was developed to report associated adding newly over 28 days. Clinical inputs were based on LIVE-AIR trial, including failure achieve survival without ventilation (SWOV), mortality, time recovery, intensive unit (ICU) admission, invasive mechanical (IMV) use....
Aim: The costs and consequences of initial delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease Canada. Materials & methods: A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined as first-line versus 3 5 years following switch from commonly therapies. Results: Ofatumumab resulted improvements clinical outcomes (relapses progression) productivity (employment full-time work),...
To estimate the clinical and economic benefits of lenzilumab plus standard care (SOC) compared with SOC alone in treatment hospitalized COVID-19 patients from National Health Service (NHS) England perspective.A cost calculator was developed to costs adding newly over 28 days. The LIVE-AIR trial results informed inputs: failure achieve survival without ventilation (SWOV), mortality, time recovery, intensive unit (ICU) admission, invasive mechanical (IMV) use. Base case included drug...
Steffens, Linda BSN, RN, CCRN; Jaeger, Stacy MS, APRN-BC; Herrmann, Susan MSN, RN; Thomas, Kimberly MSM, Barker, Katherine MSRN, CPN; Eggleston, Audrey RN Author Information
Significant and ongoing lapses in health care quality safety, the growing number of uninsured underinsured, economic crisis have ignited interest reform. As single largest group professionals, nurses will be affected by influence on these reforms. This article provides a primer administration's agenda, its historical context, way which it is likely to affect nursing. It reviews current policy directions aimed at improving quality, driving consumer selection providers, holding providers...
Abstract Purpose Estimate the clinical and economic benefits of lenzilumab plus standard care (SOC) compared with SOC alone in treatment hospitalized COVID-19 patients from National Health Service (NHS) England perspective. Methods A cost calculator was developed to estimate costs adding newly over 28 days. The LIVE-AIR trial results informed inputs: failure achieve survival without ventilation (SWOV), mortality, time recovery, intensive unit (ICU) admission, invasive mechanical (IMV) use....
Aims The study estimated the clinical benefits and budget impact of lenzilumab plus standard care (SOC) compared with SOC alone in treatment hospitalized COVID-19 patients from United States hospital perspective. Materials Methods An economic model was developed to estimate costs for an average newly patient, a 28-day time horizon index hospitalization. Clinical outcomes LIVE-AIR trial included failure achieve survival without ventilation (SWOV), mortality, recovery, intensive unit (ICU)...